NasdaqCM:IMNMBiotechs
The Bull Case For Immunome (IMNM) Could Change Following Varegacestat’s ASCO 2026 Spotlight And NDA Timeline – Learn Why
Immunome, Inc. recently announced that data from RINGSIDE, its global Phase 3 randomized, placebo-controlled trial of varegacestat in progressing desmoid tumor patients, has been selected for oral presentation at the 2026 ASCO Annual Meeting, with a New Drug Application to the US FDA planned for the second quarter of 2026.
This combination of scientific visibility at a premier oncology forum and a near-term regulatory filing highlights how Immunome is moving varegacestat toward a potential...